JMP Securities increased its price target on Halozyme (HALO) after the company announced a new partnership for its ENHANZE technology with AbbVie (ABBV). The firm notes that Halozyme received $23M in an upfront payment, and may receiveup to $130M in milestone payments for each of up to nine potential collaboration targets as well as tiered royalties on future product sales. JMP Securities thinks the company's three major ENHAZE partnership deals will enable it to surpass the firm'sroyalty projections. The firm reiterates an Outperform rating on the shares.